<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70640">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096341</url>
  </required_header>
  <id_info>
    <org_study_id>RRx001-12-01</org_study_id>
    <nct_id>NCT02096341</nct_id>
  </id_info>
  <brief_title>A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001</brief_title>
  <official_title>A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RadioRx, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RadioRx, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the dosage of RRx-001 by the subcutaneous route.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open-label, dose-escalation study of RRx-001. Subjects will receive
      RRx-001 administered as subcutaneous injections twice weekly for at least 8 weeks. At least
      three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before
      escalation to the next higher RRx-001 dose level; 2 doses—16 and 27 mg/m2— will be tested.

      The purpose of the study is to extend the dosage options for RRx-001 since faster
      subcutaneous (SC) administration may increase convenience versus the traditional IV method.
      The study also will also measure the mean concentrations of an RRx-001 metabolite in the
      blood (pharmacokinetics; PK) versus the IV formulation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of RRx-001-glutathione conjugate</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of RRx-001-glutathione conjugate</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>RRx-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses—16 and 27 mg/m2— will be tested.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RRx-001</intervention_name>
    <description>RRx-001 Dose level 1 (16 mg/m2) twice weekly
RRx-001 Dose level 2 (27 mg/m2) twice weekly</description>
    <arm_group_label>RRx-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old.

          -  ECOG (performance) status of 0, 1 or 2.

          -  Histologically or cytologically confirmed primary or metastatic advanced solid tumors
             or lymphoma. Subjects with curative treatment options are not eligible for the
             protocol.

          -  No active ongoing cancer treatment (except for prostate cancer subjects receiving
             luteinizing hormone-releasing hormone (LHRH) agonists and anti-androgens such as;
             Flutamide, Dutasteride, and Finasteride).

          -  Adequate organ and bone marrow function.

          -  Male and female subjects of childbearing potential must agree to use contraception.

        Exclusion Criteria:

          -  Pregnant or breast-feeding.

          -  Use of anti-coagulant therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynne Bui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Cancer Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Infante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan Oronsky, MD</last_name>
    <phone>650.943.2426</phone>
    <email>info@radiorx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Scicinski, PhD</last_name>
    <phone>650.943.2426</phone>
    <email>info@radiorx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Global Cancer Research Institute</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leilani H Lien, BSH, RN, PHN</last_name>
      <phone>408-384-9284</phone>
      <email>hlien@gcrioncology.com</email>
    </contact>
    <investigator>
      <last_name>Lynne Bui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Pedigo</last_name>
      <phone>615-329-7274</phone>
      <email>Heather.Pedigo@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.radiorx.com/</url>
    <description>RadioRx, Inc Home page.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
